The number of drug makers that restrict 340B discounts rose to 16 this month with announcements by Gilead and Johnson & Johnson, who plan to require that hospitals share claims data in return for discounts on drugs they buy through contract pharmacies. The drug makers say their goal is to avoid duplicate discounts, and the Pioneer Institute released a paper Tuesday (Mar. 22) with brand-friendly recommendations for reforming the 340B program, including suggestions for resolving the issues of duplicate drug...
IDP Issue:
Inside Drug Pricing - 03/28/2022